TwentyTwo GTM brain

category

market profile

• text: DNA synthesis providers need reviewable customer screening; TwentyTwo presents automated screening as available today.
• text: Functional screening and AI model safeguards are presented as previews, not generally available products.
• text: TwentyTwo is joining LatchBio, affecting the future packaging and commercial motion.

personas

• title: Biosecurity or compliance lead at a DNA synthesis provider
  pains:

  • Customer background checks are manual and time consuming
  • Needs documented evidence for screening decisions
• title: AI safety lead at a biology model developer
  pains:

  • Needs to evaluate biological misuse risk as model capabilities increase
  • Must balance access to research tools with safeguards

icp

• text: DNA synthesis and life sciences suppliers with customer vetting responsibilities; size not published.
• text: Frontier AI and AI-biology model developers are prospective partners for safeguards, which are in preview.

message pillars

• text: Screen customers faster while keeping human decisions and auditability.
• text: Build security for the expanding bioeconomy.
• text: Ground the offer in research and deployed systems.

objections

• objection: Can we trust automated screening decisions?
  response: The site says agents gather background information and the customer team makes the decision with an audit trail.
• objection: Is the full platform available now?
  response: Customer screening is available; functional screening and model safeguards are marked as coming soon.

competitors

• name: Aclid
  why: Biosecurity screening provider addressing overlapping DNA synthesis checks.
• name: SecureDNA
  why: Offers sequence screening infrastructure to DNA synthesis providers.
• name: IBBIS
  why: Its Common Mechanism is an alternative sequence screening resource.

influencers

• name: Evan Seeyave
  url: https://www.linkedin.com/posts/evanseeyave_twentytwo-is-joining-latchbio-latch-researches-activity-7477403107342299136-94K7
  why: Founder discussing the LatchBio acquisition and biosecurity mission.

keywords

• DNA synthesis customer screening
• biosecurity know your customer
• synthetic DNA screening software
• life sciences biosecurity compliance
• AI biosecurity evaluation
• biotech customer due diligence

voice

• Research grounded
• Mission driven
• Technical and direct

signals

• text: A DNA synthesis provider is formalizing or scaling customer screening and needs an audit trail.
• text: A biology model developer is building safeguards for its AI tools.

pricing

motion

channels

• website
• research publications
• LinkedIn
• partnerships

confidence

Founders

• name: Evan Seeyave
  title: Founder/CEO
  role: CEO
  bio: kurzgesagt and mango enjoyer